Fazaclo

Known as: CLOZAPINE (FAZACLO) 
 
National Institutes of Health

Related topics

Related topics

14 relations
Antipsychotic AgentsBipolar DisorderClozapine 25 MG Disintegrating Oral Tablet [Fazaclo]Comatose
(More)

Broader (1)

Clozapine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
FazaClo (clozapine) orally disintegrating tablets label
  • 2012
BECAUSE OF A SIGNIFICANT RISK OF AGRANULOCYTOSIS, A POTENTIALLY LIFE-THREATENING ADVERSE EVENT, CLOZAPINE SHOULD BE RESERVED FOR… (More)
  • figure 1
  • table 1
  • table 1
  • figure 2
  • table 2
Is this relevant?
2012
2012
Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients.
OBJECTIVE To compare the prevalence of obsessive-compulsive symptoms (OCS) in a population of patients with schizophrenia taking… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2008
2008
Bioequivalence of Clozapine Orally Disintegrating 100-mg Tablets Compared with Clozapine Solid Oral 100-mg Tablets after Multiple Doses in Patients with Schizophrenia
AbstractBackground: This study compared the bioequivalence of FazaClo® (clozapine orally disintegrating tablets) 100 mg to… (More)
Is this relevant?
Review
2007
Review
2007
Behavioral therapy for weight loss in patients with schizophrenia.
Compared with the general population, individuals with schizophrenia demonstrate an increased prevalence of obesity. While most… (More)
  • table 1
  • table 2
Is this relevant?
2007
2007
Effects of integrated treatment on antipsychotic medication adherence in a randomized trial in recent-onset schizophrenia.
OBJECTIVE Interventions improving adherence to antipsychotic medication are needed. The present study examined the effects on… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2006
Highly Cited
2006
Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: A 12-week randomized controlled clinical trial.
BACKGROUND The main objective was to assess the efficacy of a weight management program designed for outpatients taking… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
Is this relevant?
Review
2005
Review
2005
Schizophrenia and comorbid human immunodeficiency virus or hepatitis C virus.
Patients with schizophrenia are at significantly increased risk for infection with human immunodeficiency virus (HIV), hepatitis… (More)
Is this relevant?